The Innovation at a Glance
US11590171B2, titled Targeted Replacement of Endogenous T Cell Receptors, presents a cutting-edge genome editing methodology specifically designed for human T cells. The patent covers the insertion of heterologous T cell receptor (TCR) β and α chains into exon 1 of a TCR subunit constant gene. This targeted approach enhances control over T cell receptor composition, with clear implications for engineered T cell therapies, a crucial component of contemporary immunotherapy.
The Inventor & Company Behind It
This patent is assigned to University of California San Diego UCSD, a recognized academic institution with extensive expertise in biotechnology and genome editing. UCSD’s involvement underscores the foundational research strength driving innovation in this technology. The academic origin, combined with a substantial citation footprint, suggests robust scientific validation and potential for strategic collaborations or licensing in the commercial healthtech sector.
Market Opportunity
Engineered T cell therapies, such as CAR-T and related approaches, represent one of the most dynamic areas in healthtech, particularly for oncology and autoimmune diseases. Precision editing of endogenous T cell receptors could enable more effective and safer therapies by refining T cell specificity and reducing off-target effects. As the immunotherapy market expands, innovations that improve cell therapy efficacy and manufacturability become highly valuable assets.
Growth Indicators
With 167 citations, this patent demonstrates significant influence and recognition within its technical domain. Its HIS score of 72.5 reflects a strong intellectual property position, indicating relevance and potential impact. The complexity and technical depth implied by its CPC classifications (C12N, A61K) further support its role in advanced genome editing and therapeutic applications.
Why IP Investors Are Watching
The combination of a technical breakthrough in T cell receptor engineering and an academic assignee with a proven track record provides compelling reasons for investor interest. The patent’s solid citation profile signals active engagement by the scientific and patent communities, enhancing confidence in the technology’s commercial viability. Given the regulatory and manufacturing challenges in cell therapy, patent assets like this one are critical components in forming strategic partnerships and securing competitive advantage.
Get the Full Analysis
US11590171B2 exemplifies an important advance in T cell genome editing with direct ties to the immune-oncology sector. Investors focused on healthtech and immunotherapy should monitor developments around this patent for insights into emerging therapeutic modalities and licensing opportunities. Our full analytical report details the patent’s claims scope, competitive positioning, and strategic implications to support investment and due diligence activities.